Abstract
Background
This study was designed to investigate the role of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) in tumor progression and sensitivity to 5-fluorouracil (5-FU).
Methods
A total of 275 tumor samples from 275 patients with gastric cancer were utilized in this study. TS activity was determined in 130 samples by 5-fluorodeoxyuridine monophosphate binding assay. DPD activity was measured in 140 samples by radioenzymatic assay, and TP protein level was determined in 157 samples by an enzyme-linked immunosorbent assay (ELISA) system. These parameters were compared with several clinicopathologic factors and sensitivity to 5-FU determined by in-vitro ATP assay. The antitumor activities of 5-FU, uracil plus tegafur (UFT), and 1 M tegafur — 0.4 M 5-chloro-2,4-dihydroxypyridine — 1 M potassium oxonate (S-1 [TS-1®]) were also compared, using three human gastric cancer xenografts in nude mice.
Results
There was no correlation between either TS or TP and sensitivity to 5-FU. However, a weak inverse correlation was found between DPD activity and sensitivity to 5-FU. High DPD activity in tumor resulted in poor prognosis, especially in patients who received 5-FU-based adjuvant chemotherapy. Although TP was significantly correlated with depth of tumor invasion and with lymphatic and venous invasions, TP alone had no impact on survival. On the other hand, TS, as well as peritoneal, hepatic, and lymph node metastases, was selected as an independent prognostic factor in gastric cancer. In the animal model, there was no significant difference in antitumor activities among the drugs in a tumor with low DPD activity. However, S-1 showed superior antitumor activity to 5-FU or UFT in tumors with high DPD activity.
Conclusion
DPD is considered to be a most important predictive factor of 5-FU sensitivity. The use of DPD inhibitory fluoropyrimidines is strongly recommended for tumors with high DPD activity.
Article PDF
Similar content being viewed by others
References
C Heidelberger NK Chaudhuri P Dannenberg D Mooren L Griesbach R Duschinsky et al. (1957) ArticleTitleFluorinated pyrimidines, a new class of tumor-inhibitory compounds Nature 179 663–6 Occurrence Handle13418758 Occurrence Handle1:CAS:528:DyaG1cXislyn
WB Parker YC Cheng (1990) ArticleTitleMetabolism and mechanism of action of 5-fluorouracil Pharmacol Ther 48 381–95 Occurrence Handle1707544 Occurrence Handle10.1016/0163-7258(90)90056-8 Occurrence Handle1:CAS:528:DyaK3MXkt1Wns7w%3D
A Beck MC Etienne S Cheradame JL Fischel P Formento N Renee et al. (1994) ArticleTitleA role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil Eur J Cancer 30A 1517–22 Occurrence Handle7833111 Occurrence Handle1:CAS:528:DyaK2MXit1Wls7o%3D
GJ Peters CL van der Wilt CJ van Groeningen (1994) ArticleTitlePredictive value of thymidylate synthase and dihydropyrimidine dehydrogenase Eur J Cancer 30A 1408–11 Occurrence Handle7833092 Occurrence Handle1:CAS:528:DyaK2MXit1Wls70%3D
PG Johnston HJ Lenz CG Leichman KD Danenberg CJ Allegra PV Danenberg et al. (1995) ArticleTitleThymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407–12 Occurrence Handle7882343 Occurrence Handle1:CAS:528:DyaK2MXkslWis7c%3D
HJ Lenz CG Leichman KD Danenberg PV Danenberg S Groshen H Cohen et al. (1996) ArticleTitleThymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol 14 176–82 Occurrence Handle8558194 Occurrence Handle1:STN:280:DyaK287ktVaqtQ%3D%3D
PG Johnston ER Fisher HE Rockette B Fisher N Wolmark JC Drake et al. (1994) ArticleTitleThe role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer J Clin Oncol 12 2640–7 Occurrence Handle7989939 Occurrence Handle1:STN:280:DyaK2M%2FotFyjtw%3D%3D
K Miyadera T Sumizawa M Haraguchi H Yoshida W Konstanty Y Yamada et al. (1995) ArticleTitleRole of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase Cancer Res 55 1687–90 Occurrence Handle7536129 Occurrence Handle1:CAS:528:DyaK2MXltVSls7g%3D
Y Kakeji Y Maehara K Shibahara S Hasuda T Oshiro H Baba et al. (1999) ArticleTitleHeterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer Oncol Rep 6 1213–6 Occurrence Handle10523683 Occurrence Handle1:STN:280:DyaK1MvlsFWhuw%3D%3D
K Maeda YS Chung Y Ogawa S Takatsuka SM Kang M Ogawa et al. (1996) ArticleTitleThymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma Br J Cancer 73 884–8 Occurrence Handle8611421 Occurrence Handle1:CAS:528:DyaK28XjtFKhtbs%3D
N Tanigawa H Amaya M Matsumura Y Katoh A Kitaoka T Aotake et al. (1996) ArticleTitleTumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma Cancer Lett 108 281–90 Occurrence Handle8973606 Occurrence Handle10.1016/S0304-3835(96)04482-5 Occurrence Handle1:CAS:528:DyaK28Xnt1aqsrk%3D
F Yonenaga T Takasaki Y Ohi Y Sagara S Akiba H Yoshinaka et al. (1998) ArticleTitleThe expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer Pathol Int 48 850–6 Occurrence Handle9832053 Occurrence Handle1:CAS:528:DyaK1cXns1Kis7w%3D Occurrence Handle10.1111/j.1440-1827.1998.tb03851.x
Y Takebayashi S Akiyama S Akiba K Yamada K Miyadera T Sumizawa et al. (1996) ArticleTitleClinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma J Natnl Cancer Inst 88 1110–7 Occurrence Handle1:CAS:528:DyaK28Xlslyhurc%3D
AF Cook MJ Holman MJ Kramer PW Trown (1979) ArticleTitleFluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides J Med Chem 22 1330–5 Occurrence Handle533880 Occurrence Handle10.1021/jm00197a010 Occurrence Handle1:CAS:528:DyaE1MXlvVKmu7s%3D
J Schuller J Cassidy E Dumont B Roos S Durston L Banken et al. (2000) ArticleTitlePreferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 291–7 Occurrence Handle10755317 Occurrence Handle1:CAS:528:DC%2BD3cXhtlCrtLk%3D
T Ishikawa F Sekiguchi Y Fukase N Sawada H Ishitsuka (1998) ArticleTitlePositive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts Cancer Res 58 685–90 Occurrence Handle9485021 Occurrence Handle1:CAS:528:DyaK1cXht1antbc%3D
W Koizumi K Saigenji N Nakamaru I Okayasu M Kurihara (1999) ArticleTitlePrediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor Oncology 56 215–22 Occurrence Handle10202277 Occurrence Handle10.1159/000011968 Occurrence Handle1:CAS:528:DyaK1MXisFGhsbc%3D
GD Heggie JP Sommadossi DS Cross WJ Huster RB Diasio (1987) ArticleTitleClinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 2203–6 Occurrence Handle3829006 Occurrence Handle1:STN:280:DyaL2s7lvFaqtw%3D%3D
BE Harris R Song SJ Soong RB Diasio (1990) ArticleTitleRelationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion Cancer Res 50 197–201 Occurrence Handle2293556 Occurrence Handle1:STN:280:DyaK3c%2FnsFWnsA%3D%3D
CH Takimoto ZH Lu R Zhang MD Liang LV Larson LR Cantilena SuffixJr et al. (1996) ArticleTitleSevere neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency Clin Cancer Res 2 477–81 Occurrence Handle9816193 Occurrence Handle1:CAS:528:DyaK28XitVymu70%3D
MC Etienne S Cheradame JL Fischel P Formento O Dassonville N Renee et al. (1995) ArticleTitleResponse to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J Clin Oncol 13 1663–70 Occurrence Handle7602356 Occurrence Handle1:STN:280:DyaK2MzisFyrtg%3D%3D
M Terashima T Irinoda H Fujiwara T Nakaya A Takagane K Abe et al. (2002) ArticleTitleRole of thymidylate synthase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to 5-fluorouracil in human gastric cancer Anticancer Res 22 761–8 Occurrence Handle12014648 Occurrence Handle1:CAS:528:DC%2BD38XktF2nurs%3D
M Terashima H Fujiwara A Takagane K Abe T Irinoda H Yonezawa et al. (2002) ArticleTitleRole of thymidine phophorylase and dihydropyrimidine dehydrogenase on tumor progression and sensitivity to doxyfluridine Eur J Cancer 38 2375–81 Occurrence Handle12460781 Occurrence Handle10.1016/S0959-8049(02)00380-5 Occurrence Handle1:CAS:528:DC%2BD38XptFGls7Y%3D
Japanese Gastric (1998) ArticleTitleCancer Association. Japanese classification of gastric carcinoma, 2nd English edition Gastric Cancer 1 10–24
H Fujiwara M Terashima T Irinoda A Takagane K Abe M Kashiwaba et al. (2002) ArticleTitleQuantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT — PCR Jpn J Cancer Res 93 1342–50 Occurrence Handle12495474 Occurrence Handle1:CAS:528:DC%2BD3sXht12qtr8%3D
M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi et al. (1998) ArticleTitlePreclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693–8 Occurrence Handle9735397 Occurrence Handle1:CAS:528:DyaK1cXmsVClurw%3D
CP Spears AH Shahinian RG Moran C Heidelberger TH Corbett (1982) ArticleTitleIn vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas Cancer Res 42 450–6 Occurrence Handle6173112 Occurrence Handle1:CAS:528:DyaL38XhtlGntrs%3D
T Takechi H Okabe A Fujioka Y Murakami M Fukushima (1998) ArticleTitleRelationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice Jpn J Cancer Res 89 1144–52 Occurrence Handle9914783 Occurrence Handle1:CAS:528:DyaK1cXnvFygsrg%3D
H Kawamura K Ikeda I Takiyama M Terashima (1997) ArticleTitleThe usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer Eur J Cancer 33 960–6 Occurrence Handle9291821 Occurrence Handle10.1016/S0959-8049(97)00075-0 Occurrence Handle1:CAS:528:DyaK2sXks1SrtLk%3D
GJ Peters CL van der Wilt B van Triest G Codacci-Pisanelli PG Johnston CJ van Groeningen et al. (1995) ArticleTitleThymidylate synthase and drug resistance Eur J Cancer 31A 1299–305 Occurrence Handle7577040 Occurrence Handle1:CAS:528:DyaK2MXotVOmt7s%3D
ST Pullarkat J Stoehlmacher V Ghaderi YP Xiong SA Ingles A Sherrod et al. (2001) ArticleTitleThymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy Pharmacogenomics J 1 65–70 Occurrence Handle11913730 Occurrence Handle1:CAS:528:DC%2BD3MXltVSqsrc%3D
MC Etienne M Chazal P Laurent-Puig N Magne C Rosty JL Formento et al. (2002) ArticleTitlePrognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses J Clin Oncol 20 2832–43 Occurrence Handle12065560 Occurrence Handle10.1200/JCO.2002.09.091 Occurrence Handle1:CAS:528:DC%2BD38Xlt1KitLk%3D
Y Kirihara W Yamamoto T Toge M Nishiyama (1999) ArticleTitleDihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells Int J Oncol 14 551–6 Occurrence Handle10024690 Occurrence Handle1:CAS:528:DyaK1MXhs12iuro%3D
MP Findlay D Cunningham G Morgan S Clinton A Hardcastle GW Aherne (1997) ArticleTitleLack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy Br J Cancer 75 903–9 Occurrence Handle9062414 Occurrence Handle1:CAS:528:DyaK2sXitlehsbY%3D
MC Etienne X Pivot JL Formento RJ Bensadoun P Formento O Dassonville et al. (1999) ArticleTitleA multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil Br J Cancer 79 1864–9 Occurrence Handle10206306 Occurrence Handle1:CAS:528:DyaK1MXisVKlsb4%3D
S Miyamoto A Ochiai N Boku A Ohtsu M Tahara S Yoshida et al. (2001) ArticleTitleDiscrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa Int J Oncol 18 705–13 Occurrence Handle11251164 Occurrence Handle1:CAS:528:DC%2BD3MXivVWqtLk%3D
K Ogawa S Konno Y Takebayashi K Miura T Katsube T Kajiwara et al. (1999) ArticleTitleClinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma Anticancer Res 19 4363–7 Occurrence Handle10650777 Occurrence Handle1:STN:280:DC%2BD3c7hs1GmtQ%3D%3D
Y Ishikawa T Kubota Y Otani M Watanabe T Teramoto K Kumai et al. (1999) ArticleTitleDihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice Clin Cancer Res 5 883–9 Occurrence Handle10213225 Occurrence Handle1:CAS:528:DyaK1MXislOnsbo%3D
W Jiang Z Lu Y He RB Diasio (1997) ArticleTitleDihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy Clin Cancer Res 3 395–9 Occurrence Handle9815697 Occurrence Handle1:CAS:528:DyaK2sXitVKms7g%3D
S Fujii K Ikenaka M Fukushima T Shirasaka (1978) ArticleTitleEffect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil Jpn J Cancer Res 69 763–72
SD Baker SP Khor AA Adjei M Doucette T Spector RC Donehower et al. (1996) ArticleTitlePharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase J Clin Oncol 14 3085–96 Occurrence Handle8955653 Occurrence Handle1:CAS:528:DyaK2sXitl2isw%3D%3D
NJ Meropol D Niedzwiecki D Hollis RL Schilsky RJ Mayer B Cancer and Leukemia Group (2001) ArticleTitlePhase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma Cancer 91 1256–63 Occurrence Handle11283924 Occurrence Handle10.1002/1097-0142(20010401)91:7<1256::AID-CNCR1126>3.0.CO;2-V Occurrence Handle1:CAS:528:DC%2BD3MXislyhtLY%3D
T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
K Ikenaka T Shirasaka S Kitano S Fujii (1979) ArticleTitleEffect of uracil on metabolism of 5-fluorouracil in vitro Gann 70 353–9 Occurrence Handle467897 Occurrence Handle1:CAS:528:DyaE1MXltFOisLc%3D
T Taguchi (1997) ArticleTitleClinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU Oncology 54 12–8 Occurrence Handle8978579 Occurrence Handle1:CAS:528:DyaK2sXlslartw%3D%3D Occurrence Handle10.1159/000227740
R Pazdur (1997) ArticleTitlePhase II study of UFT plus leucovorin in colorectal cancer Oncology 54 19–23 Occurrence Handle8978580 Occurrence Handle1:CAS:528:DyaK2sXlslejsw%3D%3D
A Sulkes SE Benner Canetta RM. Uracil-ftorafur (1998) ArticleTitlean oral fluoropyrimidine active in colorectal cancer J Clin Oncol 16 3461–75 Occurrence Handle9779725 Occurrence Handle1:CAS:528:DyaK1cXmvFGrurg%3D
T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka et al. (1996) ArticleTitleAntitumor activity of 1 M tegafur — 0.4 M 5-chloro-2,4-dihydroxypyridine — 1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602–6 Occurrence Handle8653704 Occurrence Handle1:CAS:528:DyaK28XjtlCgurg%3D
K Tatsumi M Fukushima T Shirasaka S Fujii (1987) ArticleTitleInhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748–55 Occurrence Handle3114201 Occurrence Handle1:CAS:528:DyaL2sXlvFSntL8%3D
T Shirasaka Y Shimamoto M Fukushima (1993) ArticleTitleInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004–9 Occurrence Handle7689420 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsrk%3D
Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur — 0.4 M gimestat — 1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki et al. (1999) ArticleTitlePharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000–5 Occurrence Handle10473078 Occurrence Handle1:STN:280:DyaK1MvgtVSmtQ%3D%3D
M Fukushima A Fujioka J Uchida F Nakagawa T Takechi (2001) ArticleTitleThymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo Eur J Cancer 37 1681–7 Occurrence Handle11527696 Occurrence Handle10.1016/S0959-8049(01)00174-5 Occurrence Handle1:CAS:528:DC%2BD3MXmt1Oqtbc%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Terashima, M., Fujiwara, H., Takagane, A. et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 6 (Suppl 1), 71–81 (2003). https://doi.org/10.1007/s10120-003-0221-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0221-z